Kornimate/medical-research-clean huggingface dataset:
impact of exposure to cosmetics on sensitive skin

Conditions: Sensitive Skin; Cosmetic Exposure

Summary: the concept of sensitive or reactive skin was evoked in 1947 and developed in the 1970s and is now widely recognized. the international pruritus society has proposed an international consensus definition: sensitive skin is defined as a syndrome manifested by the occurrence of unpleasant sensations (tingling, burning, pain, pruritus, tingling) in response to stimuli that normally do not not cause such sensations. the triggering factors can be cosmetics, water, cold, heat, temperature variations, wind ... etc. the physiopathological mechanisms are debated and several hypotheses exist. sensitive skin can be considered as a decrease of the threshold of cutaneous tolerance. sensitive skin is linked to abnormalities of the cutaneous nervous system, which becomes hyper-reactive. this hyperreactivity can be modulated by multiple factors. exposure to cosmetics could be one of the main triggers for sensitive skin, especially for women. this can be explained by the wide use of cosmetics (in france women apply an average of 16 different cosmetics per day), by overconsumption of cosmetics, by exposure to potentially irritating ingredients. sensitive skin would be less tolerant to the frequent and prolonged use of cosmetics. however, no precise information is available on the actual consumption of cosmetic products in the population with sensitive skin, in particular no data exists concerning the type of products used, the criteria of choice of products, the daily number of products used. and the ingredients contained in these cosmetics

objectives are: to compare the consumption of cosmetics qualitatively and quantitatively in a group of subjects with sensitive skin in the face and scalp, with a group of subjects with non-sensitive skin study of triggers of sensitive skin localization of sensitive skin in the face resonance of sensitive skin duration of onset of skin sensitivity after application of the cosmetic use of organic products, formulated for sensitive skin, for children shopping venues for cosmetics advice from a professional for the purchase of cosmetics impact of sensitive skin on the use of cosmetics budget dedicated to the purchase of cosmetics

Eligibility criteria:
inclusion criteria: women between 18 and 65 years old - exclusion criteria: men less than 18 years old more than 65 years old skin disease on the face: acne, rosacea, eczema refusal to participate -
block-study: better local orthopedic pain control after knee arthroplasty

Conditions: Knee Arthroplasty, Total

Summary: the goal of this study is to compare the anesthetic combination ipack with femoral triangle block versus surgical lia for unilateral tka. we hypothesize that an ipack block with femoral triangle block is non-inferior to surgical lia. furthermore, due to visualization of the relevant neural and vascular structures, the risk of accidental popliteal block, nerve damage or last with (a blindly performed) lia could theoretically be reduced.


Eligibility criteria:
inclusion criteria: * asa i-iii * bmi 17-35 kg/m2 * patient is able to give informed consent * patient is scheduled for tka exclusion criteria: * refusal of patient * inability to communicate due to language or neurologic barriers * bilateral tka or unilateral knee arthroplasty * chronic opioid use (including partial opioid agonists) + chronic pain patients: * use of atypical analgesics (gabapentin, pregabalin, ...) * history of sudeck atrophy * history of \>3 chronic pain consultations * contraindications for spinal anesthesia * patient refusal * local infection * aberrant coagulation (according to the latest esra guidelines) * severe spinal canal stenosis * intracranial hypertension * history of neurological injury in the affected limb * contraindications for local anesthetics * allergy for local anesthetics * absolute contraindications for nsaids or paracetamol * proven allergy for nsaid's (including asa syndrome) or paracetamol * severe renal function impairment (egfr \<30 ml/min/1.73 m2) * active or recent (\<6 months) history of gastric ulcera/perforations/bleeding * crohn disease or colitis ulcerosa * liver function impairment or severe renal function impairment (egfr \<30 ml/min/1.73 m2) * pregnancy or breast-feeding

Keywords: ipack femoral triangle block local infiltration analgesia knee arthoplasty
power point of care effect on satisfaction of treatment

Conditions: Osteoporosis, Postmenopausal

Summary: to compare the subject satisfaction rating in women treated for postmenopausal osteoporosis with actonel 35mg once-a-week for 24 weeks, and receiving feedback information, after 12 weeks of treatment, based on bone resorption marker results using the ntx point-of-care (poc) device, to similar women treated as per regular clinical practice


Eligibility criteria:
inclusion criteria: * women diagnosed with postmenopausal osteoporosis using community practice standards * women previously non-treated for osteoporosis, or treated for osteoporosis with biphosphonates (alendronate, etidronate), hormone replacement therapy estrogen, estrogen-related drugs, progesterone, subcutaneous estrogen implant), raloxifene, fluoride, or calcitonin within the past 2 years but discontinued prior to enrolment into the study either due to:lack of effect or intolerance exclusion criteria: * subjects treated with actonelr 5 mg daily, * mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study * subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study * known/suspected hypersensitivity to any component of actonelr 35 mg once-a-week * known/suspected hypocalcaemia * known/suspected severe renal impairment (creatinine clearance \< 30ml/min) * known/suspected hyperparathyroidism * known/suspected hyperthyroidism * known/suspected active urinary tract infection * known high urine levels of calcium (3 4mg/ml) the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
characterize tumor hypoxia by magnetic resonance imaging

Conditions: Prostate Cancer; Prostate Tumor

Summary: the purpose of this research study is to measure the hypoxia (low oxygen condition) in prostate cancers and its effect in survival. in this study, investigators will assess hypoxia by magnetic resonance imaging (mri) and create a hypoxia score. investigators will study the hypoxia score and how it correlates (if any) to the disease aggressiveness as well as its effect on the treatment outcomes.

primary objective(s): * to assess hypoxia in primary prostate tumors by magnetic resonance imaging. * to correlate hypoxic score with disease aggressiveness (proliferation biomarkers' expression). secondary objective(s): * to correlate hypoxic score with exohypoxic concentration in plasma of same patient. * to correlate hypoxic score with fatty acid synthase (fasn) expression.

Eligibility criteria:
inclusion criteria: * the minimum age for this study is men 40 years and older. prostate cancer mainly affects men over the age of 40. * patients with caucasian and african american race * patients with pathology-proven prostate cancer (gleason 6 or higher) * patients who have not yet undergone therapy (systemic drugs, radiation, or prostatectomy) * patients who will have a radical prostatectomy as standard of care. * ability to understand and the willingness to sign an irb-approved informed consent document (either directly or via a legally authorized representative). exclusion criteria: * patients who have already received some form of treatment or are not planning to undergo radical prostatectomy for treatment. * patients with any other cancer along with prostate cancer. * uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
trial in subjects undergoing cardiac catheterization with planned percutaneous coronary intervention with stenting

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary intervention (pci).


Eligibility criteria:
inclusion criteria: * subjects greater than or equal to 18 years of age undergoing cardiac catheterization with planned percutaneous coronary intervention (if coronary anatomy is suitable) for an indication of chest pain +/or anginal equivalent felt by the treating physician to be related to coronary ischemia. * at least one of the following (a through c): 1. functional study (exercise, or pharmacologic) within the past 8 weeks consistent with ischemia as manifested by at least one of the following: 1. a reversible defect on nuclear imaging. 2. a reversible wall-motion abnormality by echocardiography. 3. horizontal or down-sloping st-depressions greater than 1 mm on electrocardiogram (ecg) (if no imaging performed). 2. prior coronary revascularization \[percutaneous coronary intervention (pci) or coronary artery bypass graft (cabg)\]. 3. a cardiac catheterization with at least one coronary artery lesion amenable to pci (not yet performed) within 14 days prior to enrollment. exclusion criteria: * known creatine kinase-myocardial bands (ck-mb)or cardiac troponin greater than the upper limit of normal at time of screening * planned pci for acute myocardial infarction (mi) or planned pci within 48 hours of fibrinolytic therapy for st segment elevation myocardial infarction (stemi) * have cardiogenic shock at the time of screening (systolic blood pressure 90 mm hg associated with clinical evidence of end-organ hypoperfusion, or subjects requiring vasopressors to maintain systolic blood pressure over 90 mm hg and associated with clinical evidence of end-organ hypoperfusion). * refractory ventricular arrhythmias * have new york heart association class iv congestive heart failure
diagnostic accuracy of rapid molecular tests for group a streptococcal pharyngitis using saliva samples

Conditions: Streptococcal Pharyngitis

Summary: observational study evaluating the diagnostic accuracy of rapid point-of-care molecular group a strep diagnostic tests in saliva as compared to standard culture- and pcr-based techniques for the management of children aged 3-15 years of age presenting with sore throat to primary care.

group a streptococcus (gas) is found in 20% to 40% of cases of childhood pharyngitis; the remaining cases are viral. streptococcal pharyngitis ('strep throat') deserves antibiotics, while these are not indicated in viral cases. because signs and symptoms of streptococcal and viral cases overlap, most guidelines recommend relying on a diagnostic test to identify group a streptococcus to select who should receive antibiotics. in most settings, the first-line test to detect group a streptococcus is a rapid antigen detection test based on a throat swab, and the reference standard to identify streptococcal cases is throat culture. recently, new rapid tests were developed. they use molecular techniques, such as rapid pcrs or lamp, based on throat swabs. we hypothesize that these new molecular tests are sensitive enough to be performed on saliva swabs instead of throat swabs. collecting saliva is less invasive and could be done by personnel with limited training.

Eligibility criteria:
inclusion criteria: * children 3-15 years * seen in primary care (general practitioner or primary care pediatrician) * with a diagnosis of acute pharyngitis defined as an inflammation of the pharynx and/or tonsils (erythema with or without exudate) or acute sore throat (even if without local signs of pharyngeal inflammation) * non-opposition of the accompanying parent(s) exclusion criteria: * children who received antibiotics within 7 days before inclusion * children already enrolled in the study for the same episode of pharyngitis

Keywords: sore throat, rapid tests, molecular tests, saliva, sensitivity, specificity
post operative pain management for acl reconstruction

Conditions: Pain, Postoperative

Summary: health care providers are seeking methods to limit post-operative pain and opioid prescriptions to reduce the burden of the national opioid use epidemic. adductor canal block (acb) is a peripheral nerve block that has been shown to reduce pain and opioid usage with minimal effect on quadriceps function in patients undergoing arthroscopic knee surgery. infiltration between popliteal artery and capsule of the knee (ipack) block has also shown promise in reducing pain and opioid usage, specifically reducing posterior knee pain, which acb is not able to achieve. to our knowledge, there is currently no study in the orthopedic literature comparing post-operative pain and opioid consumption in acl reconstruction (aclr) patients who received isolated acb versus acb with ipack. the primary aim of this study is to investigate the role of ipack in combination with acb in reducing peri-operative (14-days) pain levels in aclr patients. the secondary aim is to determine the effectiveness of ipack in reducing post-operative opioid use. the tertiary aim is to determine any effect of ipack on post-operative functional outcomes.


Eligibility criteria:
inclusion criteria: * all patients undergoing primary aclr for acl tear, including patients with concomitant meniscectomy or meniscal repair. exclusion criteria: * revision aclr, worker's compensation, pregnancy, age\<18 years
application of preoperative axillary lymph node marking with nano-carbon in breast cancer patients before neoadjuvant chemotherapy

Conditions: Breast Cancer; Neoadjuvant Therapy; Sentinel Lymph Node Biopsy

Summary: the primary aim of this prospective, multicentre study is to determine whether the involved node can be marked using black carbon dye and successfully identified at the time of surgery. the secondary aims are to determine the concordance between the tattooed node and sentinel node, migration of black dye into other nodes, and false-negative rate of tattooed node (in patients undergoing alnd after nact).

pretreatment evaluation of axillary lymph nodes and marking of biopsied nodes in patients with newly diagnosed breast cancer is becoming routine practice. tagging of biopsied axillary lymph nodes with metal markers, similar to what is done for suspicious breast lesions, is being adopted in clinical practice. the need to mark a positive axillary lymph node becomes especially relevant in cases where neoadjuvant chemotherapy (nact) is anticipated so that these nodes may be identified at the time of surgery. measures that improve both the accuracy of nodal evaluation after nact and the ability to assess treatment response are desirable in order to tailor therapies for breast cancer treatment. the investigators sought to test tattooing of biopsied axillary lymph nodes with a sterile black carbon suspension.

Eligibility criteria:
inclusion criteria: 1. female; 2. aged \>=18 years; 3. with invasive breast cancer; 4. patients to be treated with neoadjuvant chemotherapy; 5. patients scheduled to undergo routine fine needle aspiration (fna) or core biopsy of abnormal axillary lymph node; 6. patients with operable breast cancer; 7. heart, lung, liver and kidney function well, suitable for patients undergoing surgery; 8. informed consent patients. exclusion criteria: * 1. patients who do not plan or are unable to operate; 2. patients with distant metastasis were excluded; 3. patients without invasive cancer components in dcis alone; 4. patients who are unable to cooperate with the doctor's recommended surgical treatment (breast conserving surgery or radical surgery) due to personal or family factors; 5. patients with serious cardiopulmonary diseases, uncontrolled infectious diseases and other non tumor related diseases who can not tolerate comprehensive treatment such as surgery and chemotherapy; 6. patients with mental illness or other reasons unable to sign informed consent; 7. patients with poor medical compliance who cannot complete the trial treatment process and follow-up according to the standard according to the researcher's opinion.
assessing the impact of probiotic supplementation in children diagnosed with autism spectrum disorder: the probi-o-tism study

Conditions: Autism Spectrum Disorder

Summary: children with autism spectrum disorder (asd) present with stereotyped behaviors and often with comorbidities including gastrointestinal symptoms and sleep disturbances. these affect the quality of life of both children and parents. as of now, interventions available to manage asd-related behaviors rely heavily on the services of professionals who are often difficult to access. what is even more striking is that there are currently no approved medications to treat the core symptoms of asd. there is an important need for additional strategies to manage severity of asd and to develop new treatments. targeting the bacteria living in the intestine, named 'gut microbiota', by using probiotics is an avenue that has been proposed by other groups to improve behaviors associated with asd and gastrointestinal symptoms. however, these studies have important limitations, pressing the need for robustly designed interventions. previously, the probi-o-tism pilot study was conducted at chu sainte-justine. the investigators confirmed that the bio-k+ probiotic beverage is acceptable and safe for autistic children and that the proposed study protocol is feasible. the study also led to promising preliminary results suggesting a beneficial effect of the probiotics on behaviors, gastrointestinal symptoms and sleep. the proposed study will answer the question: ''does supplementing with bio-k+ probiotics reduce the severity of autistic behaviors and comorbidities in children with a diagnosis of asd? '' the investigators will use a solid study design, a double-blinded randomized controlled-trial with placebo, to test the efficacy of a 14-week treatment with daily bio-k+ probiotic supplement in children aged 4 to 11 years old. the investigators will also study the impact of the supplementation on other parameters such as quality of life, gut microbiota and brain signaling. this is a unique opportunity to test a simple approach to improve behaviors and comorbidities in autistic children.


Eligibility criteria:
inclusion criteria: * being an autistic child with normal intelligence as documented by a neuropsychology assessment at the time of asd diagnosis based on the ados score and the clinical impression of a multidisciplinary team of experts in autism diagnosis in the department of psychiatry; * being between the ages of 4 and 11 years; * acceptance and ability of the child to consume the probiotics product. exclusion criteria: * epilepsy; * autism in the context of a genetic syndrome such as fragile x or bourneville sclerosis; * known presence of cancer, diabetes, celiac disease or inflammatory bowel disease (crohn's disease or ulcerative colitis); * genetic disorder such as trisomy 21 or 14; * immune system disorder; * intolerance or allergy to bio-k+ pea-based probiotics; * having taken antibiotics or probiotics in the previous 3 months

Keywords: gastrointestinal symptoms sleep disorder probiotics microbiota autism spectrum disorder
a study in hormone receptor-positive metastatic breast carcinoma patients to test a new schedule of efti (imp321, eftilagimod alpha) as adjunctive to a weekly treatment regimen of paclitaxel

Conditions: Metastatic Breast Cancer

Summary: this is a multicentre, multinational phase ib study in female hr+ mbc patients not receiving her2-targeted therapy. treatment consists of a chemo-immunotherapy phase followed by a maintenance phase. the chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. during each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on day 1, 8 and 15 and 30 mg efti subcutaneously on day 1 and 15 in a 28-day (4-week) cycle. efti will always be given after paclitaxel. the maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneously as monotherapy. a total of 24 subjects will be enrolled into the study. the primary goal of the study is safety and tolerability profile of efti in combination with weekly paclitaxel both given the same day in contrast to subsequent days as in the aipac trial.

this is a multicentre, multinational phase ib study in female hr+ mbc patients not receiving her2-targeted therapy. treatment consists of a chemo-immunotherapy phase followed by a maintenance phase. the chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. during each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on day 1, 8 and 15 and 30 mg efti subcutaneously on day 1 and 15 in a 28-day (4-week) cycle. efti will always be given after paclitaxel. the maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneously as monotherapy. a total of 24 subjects will be enrolled into the study. the primary goal of the study is safety and tolerability profile of efti in combination with weekly paclitaxel both given the same day in contrast to subsequent days as in the aipac trial.

Eligibility criteria:
inclusion criteria (selected ones): * metastatic oestrogen receptor positive and/or progesterone receptor positive breast adenocarcinoma, histologically proven by biopsy of the primary tumour and/or a metastasis * subjects who are indicated to receive first line chemotherapy with weekly paclitaxel * ecog performance status 0-1 * expected survival longer than three months exclusion criteria (selected ones): * prior chemotherapy for metastatic breast adenocarcinoma * disease-free interval of less than twelve months from the last dose of adjuvant chemotherapy * prior high-dose chemotherapy requiring hematopoietic stem cell rescue * inflammatory carcinoma at time of screening * candidate for treatment with trastuzumab (or other her2/neu targeted agents) or endocrine based therapy according to the applicable treatment guidelines * systemic chemotherapy, radiation therapy or any other investigational agent within 4 weeks, endocrine therapy within 1 week or cdk4/6 inhibitors within 5 times half-life (acc. to spc) prior to first dose of study treatment * symptomatic known cerebral and/or leptomeningeal metastases